SEC FORM 3

SEC FORM 3SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Xu Cong Claire

(Last)

(First)

(Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares⁽¹⁾	288,266⁽²⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
2021 Employee Share Option (right to buy)	⁽⁴⁾	06/08/2031	Ordinary Shares⁽¹⁾	22,900⁽³⁾	$60.7⁽³⁾	D
2022 Employee Share Option (right to buy)	⁽⁵⁾	03/04/2032	Ordinary Shares⁽¹⁾	43,690⁽³⁾	$21.15⁽³⁾	D
2023 Employee Share Option (right to buy)	⁽⁶⁾	07/04/2032	Ordinary Shares⁽¹⁾	57,660⁽³⁾	$5.55⁽³⁾	D
2024 Employee Share Option (right to buy)	⁽⁷⁾	05/30/2034	Ordinary Shares⁽¹⁾	146,865⁽³⁾⁽⁷⁾	$1.74⁽³⁾	D
2024 Employee Share Option (right to buy)	⁽⁸⁾	09/03/2034	Ordinary Shares⁽¹⁾	52,165⁽³⁾	$1.05⁽³⁾	D
Restricted Share Units	⁽⁹⁾	⁽⁹⁾	Ordinary Shares⁽¹⁾	36,716⁽³⁾	⁽⁹⁾	D
Restricted Share Units	⁽¹⁰⁾	⁽¹⁰⁾	Ordinary Shares⁽¹⁾	5,405⁽³⁾	⁽¹⁰⁾	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Reported securities are represented by 123,594 ADSs.

3. Number of underlying securities and exercise price expressed in terms of ADSs.

4. The option was granted on July 21, 2021 and is fully vested and exercisable.

5. The option was granted on March 4, 2022 and is fully vested and exercisable.

6. The option was granted on January 4, 2023. The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of the grant date.

7. The option to purchase 195,820 ADSs was granted on May 30, 2024. The option vested or shall vest and become exercisable over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. Amount of underlying securities excludes a portion of the option that has vested and been exercised.

8. The option was granted on September 3, 2024 and is fully vested and exercisable. Amount of underlying securities excludes a portion of the option that has vested and been exercised.

9. On May 30, 2024, the Reporting Person was granted 65,270 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.

10. On January 4, 2023, the Reporting Person was granted 21,620 RSUs. The RSUs vested or shall vest in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Senior Vice President, Clinical Development Exhibit List: Ex. 24.1 - Power of Attorney

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

SEC Form 3 filed by new insider Xu Cong Claire